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Objectives. This study investigated the role of neuronal uptake 
of norepinephrine (uptake-l) in human heart failure as a local 
factor for altering concentrations of norepinephrine atthe cardiac 
myocyte membranes. 
Background. Several beta-adrenergic neuroeffector defects oc- 
cur in heart failure. Whether an alteration in norepinephrine 
uptake-1 occurs is still unresolved. 
Methods. The role of norepinephrine uptake-1 was studied in 
electrically stimulated (1 Hz, 37°C) human ventricular cardiac 
preparations and isolated myocardial membranes. 
Results. The effectiveness of norepinephrine in increasing the 
force of contraction was decreased in relation to the degree of 
heart failure. In contrast, the potency of norepinephrine was 
increased in failing hearts (New York Heart Association func- 
tional class IV) in relation to the concentrations producing 50% of 
the maximal effect (ECso). The ECso values for isoproterenol, 
which is not a substrate for norepinephrine uptake-l, were 
reduced in myocardium in functional classes II to III and IV 
compared with those in nonfailing myocardium. The uptake 
inhibitors cocaine and desipramine (3/~mol/liter) potentiated the 
positive inotropic effects of norepinephrine in nonfailing myocar- 
dium (p < 0.05) but not in functional class IV myocardium. 
Radioligand binding experiments using the uptake inhibitor lay- 
drogen-3 mazindol revealed a significant decrease by -30% in 
norepinephrine uptake-1 carrier density in functional classes II to 
III and IV myocardium versus nonfailing myocardium (p < 0.05). 
Conclusions. In human heart failure, there is a presynaptic 
defect in the sympathetic nervous system, leading to reduced 
uptake-1 activity. This defect in the failing heart can be mimicked 
by the effects of uptake blocking agents, such as cocaine and 
desipramine, in the nonfailing heart only. Compromised norepi- 
nephrine uptake-1 in functional class IV cannot be further 
increased by cocaine and desipramine. The pathophysiologic 
consequences could be an increased synaptic concentration of 
norepinephrine predisposing to adenylyl cyclase desensitization. 
(J Am Coil Cardiol 1995;25:146-53) 
In failing human myocardium, the blunted cardiac responsive- 
ness to beta-adrenergic stimulation is due to a reduction in 
betal-adrenoceptor density (1,2) and an increase in Gi-alpha 
proteins (3-5), which could be induced by an increased level of 
circulating catecholamines (6-8), an increase in neuronal 
release of norepinephrine (9) or an impairment of neuronal 
uptake of norepinephrine, or a combination of these mecha- 
nisms. Cardiac neuronal uptake is the predominant mechanism 
for terminating the action of norepinephrine on beta- 
adrenoceptors when catecholamines are released by sympa- 
thetic nerve terminals (10). In patients with heart failure, data 
arguing against (11,12) or in favor (13) of reduced myocardial 
norepinephrine uptake exist. However, direct experimental 
evidence in isolated failing human myocardium in favor of 
reduced norepinephrine uptake as well as its potential func- 
tional consequences is limited. The purpose of this study was to 
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use functional and biochemical techniques to investigate the 
role of neuronal uptake of norepinephrine (uptake-i) in 
human heart failure as a local factor for altering concentra- 
tions of norepinephrine at the cardiac myocyte membranes. 
Studies were performed in electrically stimulated human ven- 
tricular cardiac preparations and isolated myocardial mem- 
branes. Tissue was obtained from patients who underwent 
mitral valve replacement or heart transplantation. For com- 
parison, tissue from nonfailing donor hearts was studied. 
Methods  
Myocardial tissue. Myocardium from terminally failing 
human hearts was obtained from patients after cardieetomy 
during cardiac transplantation. The patients had dilated or 
ischemic ardiomyopathy and were in New York Heart Asso- 
ciation functional class IV on the basis of clinical symptoms 
and signs as judged by the attending cardiologist shortly before 
operation. During mitral valve replacement, tissue from mod- 
erately failing hearts was obtained. All patients gave written 
informed consent before operation. Clinical details of the 
patients included in the study are shown in Table 1. Flunitraz- 
epam and pancuronium bromide with isoflurane were used for 
general anesthesia. Cardiac surgery was performed during 
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Table 1. Clinical Characteristics Obtained at Preoperative Cardiac Catheterization f r Patients Providing Study Myocardium Samples 
LVEDP LVEDV EF CI 
Gender/Age (yr) NYHA Diagnosis (mm Hg) (ml) (%) (liters/min × m 2) 
Mitral Valve Replacement 
Mean 
_+SEM 
F/57 II-III MR 12 116 74 2.4 
F/67 lI-I I I  MR 10 263 45 2.1 
F/46 I1-Ili MR > MS 15 149 58 3.1 
M/44 II-III MS > MR 10 76 60 1.7 
M/46 II-III MR 12 384 49 3.2 
M/59 II-III MR 20 62 53 1.4 
F/65 II-II1 MS 3 63 76 2.4 
F/68 II-III MS 15 259 54 3.1 
56.5 II-I I I  12.1 171.5 58.6 2.4 
+3.5 _+1.6 _+39.1 _+3.7 _+0.2 
Cardiac Transplantation 
Mean 
_+SEM 
I71/55 IV DCM 20 364 14 2.0 
M/50 IV DCM 22 424 15 2.2 
M/47 IV DCM - -  - -  - -  1.4 
M/42 IV DCM 14 290 21 3.2 
M/51 IV DCM 16 208 21 2.2 
M/49 IV DCM 41 532 14 1.9 
M/39 IV ICM 28 178 49 3.5 
M/63 IV ICM . . . .  
M/48 IV ICM 28 92 29 1.6 
49.3 24.1 298.3 23.3 2.3 
_+2.2 _+2.6 _+53.5 _+4.4 _+0.2 
CI = cardiac index; DCM = dilated cardiomyopathy; EF - ejection fraction; F - female; ICM = ischemic ardiomyopathy; LVEDP = left ventricular end-diastolic 
pressure; LVEDV - left ventricular end diastolic volume; M - male; MR = predominant mitral regurgitation; MS = predominant mitral stenosis; NYHA = New 
York Heart Association functional class (II to III - moderately failing myocardium, IV = severely failing myocardium); - - = data not available. 
cardiopulmonary bypass with cardioplegic arrest during hypo- 
thermia. The cardioplegic solution (modified Bretschneidcr 
solution) contained (in mmol/liter) NaCI 15, KC1 10, MgC12 4, 
histidine 180, tryptophan 2,mannitol 30 and potassium dihy- 
drogen oxoglutarate 1. Nonfailing myocardium was obtained 
from five donors who were declared brain dead as a result of 
traumatic injury. These hearts could not be transplanted for 
technical reasons. Echocardiographic evaluation showed nor- 
mal left ventricular function. Invasive hemodynamic measure- 
ments were not performed. None of the donors of the nonfail- 
ing hearts received sustained catecholamine treatment. 
However, bolus injections of catecholamines were documented 
in three patients during resuscitation after acute treatment of
trauma. Thus, these hearts cannot be termed normal but only 
nonfailing. The reasons for not transplanting the hearts were 
fever, pericardial effusion or evidence for coronary heart 
disease. The use of human cardiac tissues was approved by the 
ethical committees ofthe Universities of Munich and Cologne. 
Isolated cardiac preparation and measurement of force of 
contraction. Immediately after excision, papillary muscle 
strips were placed in ice-cold preaerated!.Tyrode solution and 
delivered to the laboratory within 10 min. The experiments 
were performed on isolated electrically driven muscle prepa- 
rations. Muscle strips of uniform size with muscle fibers 
running approximately parallel to the length of the strips were 
dissected under microscopic ontrol using scissors in aerated 
modified Tyrode solution (see composition later). Connective 
tissue was carefully trimmed away. The muscles were sus- 
pended in an organ bath (75 ml) maintained at 37°C and 
containing a modified Tyrode solution of the following com- 
position (in retool/liter): NaC1 119.8, KC1 5.4, MgC12 1.05, 
CaC12 1.8, NaHCO 3 22.6, NaH2PO 4 0.42, glucose 5.0, ascorbic 
acid 0.28, ethylenediaminetetraacetic acid (EDTA) 0.05. The 
bathing solution was continuously aerated with 95% oxygen 
and 5% carbon dioxide. The muscles were stimulated by two 
platinum electrodes using field stimulation from a Grass $88 
stimulator (frequency 1 Hz, impulse duration 5 ms, intensity 
10% to 20% greater than threshold). Each muscle was 
stretched to the length at which force of contraction was 
maximal. The force at rest was kept constant throughout the 
experiment. The resultant tension was measured isometrically 
with an inductive force transducer (W. Fleck, Mainz, Ger- 
many) attached to a Gould recorder. Preparations were al- 
lowed to equilibrate for at least 90 min, with the bathing 
solution changed once after -45 min. Experimental details 
have been described elsewhere (3). 
Membrane preparation and radioligand binding experi- 
ments. Left ventricular myocardial tissue was chilled in 30 ml 
of ice-cold homogenization buffer (20 mmol/liter of tris(hy- 
droxymethyl)aminomethane [Tris] hydrochloride, 4 mmol/liter 
of EDTA and 1 mmol/liter of dithiotheitol, pH 7.4). Connec- 
tive tissue was trimmed away; myocardial tissue was minced 
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with scissors; and membranes were homogenized with a motor- 
driven glass-Teflon homogenizer for 1 min. The membrane 
preparation was then homogenized byhand with a glass-glass 
homogenizer. The homogenate was spun at 484 g (Beckman 
JA 20 rotor) for 15 min. The supernatant was filtered through 
four layers of gauze, diluted with an equal volume of potassium 
chloride (1 mol/liter) and stored on ice for 10 min. This 
suspension was centrifuged at100,000 g for 30 min. The pellet 
was resuspended in 50 volumes of incubation buffer (50 
mmol/liter of Tris He1, 120 mmol/liter of NaC1, 5 mmol/liter of 
KC1, pH 7.4) and homogenized for 1 rain with a glass-glass 
homogenizer. This suspension was recentrifuged at100,000 g 
for 45 min. The final pellet was resuspended in incubation 
buffer and stored at -80°C. Storage did not alter the results. 
Protein was measured according to Lowry et al. (14) using 
bovine serum as standard. The assays were performed ina total 
volume of 250/zl. The incubation was carried out at 22°C for 
60 min. These conditions allowed complete quilibration of 
the receptor with the radioligand. The reaction was terminated 
by rapid vacuum filtration through Whatman GF/C filters 
that were presoaked with 0.1% 3-([3-chelamidopryl]- 
dimethylamonio)-l-propansulfate (CHAPS) to reduce nonspe- 
cific binding. The filters were washed immediately three times 
with 6 ml of ice-cold incubation buffer to remove any unbound 
radioligand. All experiments were performed in triplicate. 
Radioactivity was determined in an LKB counter (Pharmacia 
LKB, Freiburg, Germany). Myocardial norepinephrine uptake 
carrier sites were studied using hydrogen-3 (H-3) mazindol 
(specific activity 24.7 Ci/mmol) as radiolabeled ligand (1 to 50 
nmol/liter). Specific binding of H-3 mazindol was defined in 
the presence of desipramine (100/smol/liter). 
Materials. (S)-(-)-Norepinephrine was from Merck- 
Schuchardt (Hohenbrunn, Germany). Atropine sulfate and 
desipramine were purchased from Sigma Chemie GmbH 
(Deisenhofen, Germany). Cocaine solution was prepared in 
the pharmacy of the Klinikum GroBhadern (University of 
Munich). Hydrogen-3 mazindol (specific activity 24.7 Ci/ 
mmol) was from New England Nuclear-DuPont GmbH 
(Dreieich, Germany). All other compounds used were of 
analytic grade or the best grade commercially available. Only 
deionized and twice-distilled water was used throughout. 
Statistical evaluation. All data are mean value _SEM. 
Statistical significance was estimated with the Student t test for 
unpaired observations and analysis of variance. The Scheff6 
procedure for multiple comparisons was applied. A p value 
<0.05 was considered significant. The drug concentrations 
producing 50% of the maximal effect (ECs0) were graphically 
determined for each individual experiment. 
Results 
Effects of norepinephrine and isoproterenol. Figure 1 
shows the positive inotropic effects of norepinephrine in
isolated electrically driven papillary muscle strips from mod- 
erately (functional classes II to III) and severely (functional 
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Figure l. Concentration-response curv s for the effect of norepineph- 
rine (0.01 to 100 ~mol/liter) on isometric force of contraction i
isolated electrically driven papillary muscle strips from nonfailing 
donor hearts (NF) and from patients undergoing mitral valve replace- 
ment (New York Heart Association [NYHA] functional classes II to 
III) or cardiac transplantation (functional class IV). 
class IV) failing as well as nonfailing myocardium. Norepi- 
nephrine concentration dependently increased force of con- 
traction in both groups. As expected, the positive inotropic 
effect of norepinephrine was reduced in papillary muscle strips 
from functional classes II to III and IV compared with that in 
nonfailing myocardium. To evaluate the potency of the beta- 
adrenoceptor agonist, concentration-response curves for nor- 
epinephrine are shown in percent of the maximal effect in each 
preparation. Unexpectedly, the potency of norepinephrine to 
increase force of contraction was increased in functional 
classes II to III and IV myocardium compared with nonfailing 
myocardium (Fig. 1, bottom). Correspondingly, the EC5o val- 
ues were significantly lower in failing than in nonfailing 
myocardium (Table 2). The increased potency of norepineph- 
rine despite reduced maximal effects could either eflect more 
efficient coupling of the remaining beta-adrenoceptors r a 
reduced inactivation of norepinephrine byuptake-1 in failing 
myocardium. To address the latter, we compared the effects of 
norepinephrine with those of isoproterenol, which is not a 
substrate for uptake-1 (15,16), under same experimental con- 
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Table 2. ECs0 Values for Effect of Isoproterenol and Norepinephrine Alone or With Cocaine 
or Desipramine 
ECso Values (/zmol/liter) 
Study Conditions NF NYHA II-III NYHA IV 
Isoproterenol 0.016 (0.01-0.02) 0.026 (0.02-0.04)* 0.06 (0.04-0.08)* 
NE 1.7 (1.21-2.43) 0.50 (0.22-1.14)* 0.59(0.3-1.15)* 
NE + cocaine 0.58 (0.36-0.94)1 0.28 (0.12-0.66) 1.1 (0.43-2.86) 
NE + desipramine 0.51 (0.19-1.35)~ 0.27 (0.11-0.67) 0.85 (0.13-5.45) 
*p < 0.05 versus nonfailing rnyocardium (NF). "~p < 0.05 versus norepinephrine (NE). ECso values = concentration 
producing half-maximal effects (range); NYHA = New York Heart Association functional class (see Table 1). 
ditions. The results are summarized in Figure 2. As with 
norepinephrine, the maximal effects of isoproterenol were 
reduced in relation to the severity of heart failure (Fig. 2, top). 
As shown in Figure 2, bottom, the effects of isoproterenol were 
less potent in failing than in nonfailing myocardium, also in 
relation to the stage of the disease. Consistently, the ECso 
values were significantly higher in functional classes II to III 
and IV myocardium than in nonfailing myocardium. In sum- 
mary, opposing results on the potency to increase force of 
Figure 2. Concentration-response curves for the effect of isoprotere- 
nol (isoprenaline) (0.0001 to 1 #mol/liter) on isometric force of 
contraction i  isolated electrically driven papillary muscle strips from 
nonfailing donor hearts (NF) and from patients undergoing mitral 
valve replacement (New York Heart Association [NYHA] functional 
classes II to III) or cardiac transplantation (functional class IV), 
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contraction were obtained with isoproterenol, which is not a 
substrate for uptake-1 (15,16), and the physiologically occur- 
ring beta-adrenoceptor agonist norepinephrine, which is pri- 
marily inactivated by uptake-l, uptake into presynaptic stores 
(17). 
To further substantiate he evidence for a reduced uptake-1 
in failing myocardium, experiments with the uptake-1 inhibi- 
tors desipramine and cocaine were performed. Some differ- 
ence in the effect of these uptake-1 inhibitors on the concen- 
tration-response curve of norepinephrine in the different 
groups could be expected if there was an alteration in norepi- 
nephrine carrier. Figure 3 shows concentration-response 
curves for norepinephrine alone and in the presence of desi- 
pramine (3 /zmol/liter) or cocaine (3 /~mol/liter) in cardiac 
preparations from nonfailing myocardium. At 3/~mol/liter of 
desipramine or cocaine, force of contraction was reduced by 
-15% (not shown). Higher concentrations were not used 
because of the negative inotropic effects of the uptake-1 
inhibitors. Cocaine and desipramine shifted the concentration- 
response curve of norcpinephrine to the left in nonfailing 
myocardium. The EC50 values were significantly reduced com- 
pared with those for norepinephrine alone (Table 2). Figure 4 
summarizes the data in functional class IV myocardium. 
Neither desipramine nor cocaine affected the concentration- 
Figure 3. Concentration-response curves for the effects of norepi- 
nephrine (0.01 to 100/~mol/liter) alone and in the presence of cocaine 
(3 /~mol/liter) or desipramine (3 /zmol/liter) on isometric force of 
contraction i  isolated electrically driven papillary muscle strips from 
nonfailin donor hearts. 
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Figure 4. Concentration-response curves for the effects of norepi- 
nephrine (0.01 to 100/zmol/liter) alone and in the presence of cocaine 
(3 /smol/liter) or desipramine (3 /~mol/liter) on isometric force of 
contraction i  isolated electrically driven papillary muscle strips from 
patients undergoing heart ransplantation (New York Heart Associa- 
tion [NYHA] functional class IV). 
response curves in functional class IV myocardium. The ECso 
values of norepinephrine alone or in the presence of cocaine or 
desipramine in functional class IV myocardium were not 
significantly different from those in nonfailing myocardium in 
the presence of uptake-1 inhibitors. Thus, uptake-1 inhibition 
in nonfailing myocardium produced a situation similar to that 
in failing myocardium under control conditions. 
Norepinephrine uptake carrier sites. To quantitate norepi- 
nephrine uptake carrier sites directly, radioligand binding 
experiments were performed in functional classes II to III and 
IV myocardium and in nonfailing myocardium. Hydrogen-3 
mazindol binding experiments were performed as described 
elsewhere (18). Hydrogen-3 mazindol binding was strongly 
NaC1 dependent. Maximal specific binding was obtained in the 
presence of 120 mmol/liter of NaCI (not shown). Radioligand 
saturation binding experiments (in the presence of 120 mmol/ 
liter of NaC1) revealed concentration-dependent binding of the 
radioligand. Scatchard (19) analysis of the binding data showed 
monophasic binding with a specific binding of -30% at the 
dissociation constant (Ko) (not shown). The density of norepi- 
nephrine uptake carrier sites obtained with these techniques i
shown in Figure 5. There was a reduction by -30% in uptake 
sites in functional classes II to III and IV myocardium com- 
pared with nonfailing myocardium (p < 0.05). The absolute 
numbers and K o values are summarized in Table 3. 
Discussion 
It is widely accepted that there is a general activation of the 
sympathetic nervous system in heart failure (6-8,20), which 
results in increased circulating norepinephrine l vels at rest 
and during exercise (6-8) and correlates with the prognosis of 
patients with heart failure (6,8). In addition, Swedberg et al. 
(9) observed an increased release of norepinephrine from the 
myocardium of patients with heart failure compared with 
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Figure 5. Density of norepinephrine uptake carrier sites in cardiac 
membranes from the human left ventricle from nonfailing (NF) donor 
hearts and from patients undergoing mitral valve replacement (New 
York Heart Association [NYHA] functional classes II to III) and heart 
transplantation (functional class IV). Densities were investigated with 
radioligand saturation experiments. See Methods. 
control subjects. The latter finding could result from increased 
activity of myocardial sympathetic neurons or impaired uptake 
of norepinephrine from the synaptic cleft, or both. Further 
evidence for local alteration of myocardial norepinephrine 
(i.e., uptake, release and synthesis) has been reported. There 
are reduced stores of myocardial norepinephrine (18,21,22) 
and a reduced myocardial turnover, including defects in cate- 
cholamine synthesis (23,24) as well as reduced effects of the 
indirectly acting sympathomimetic drugs tyramine (25) and 
dopexamine (26). Controversy exists about the involvement of 
norepinephrine uptake site mechanisms in heart failure. Rose 
et al. (13) reported a reduction in the rate of norepinephrine 
uptake and of norepinephrine r lease with a multiple indicator 
technique and reported a reduction in norepinephrine r lease 
from the myocardium of patients with dilated cardiomyopathy. 
However, Hasking et al. (12) provided evidence for unchanged 
norepinephrine uptake as judged from the kinetics of tritiated 
norepinephrine constantly applied to the myocardium of pa- 
tients with heart failure. In agreement with the latter report, 
Meredith et al. (11) reported ata on the cardiac outflow of the 
norepinephrine precursor dihydroxyphenylalanine, the intra- 
neural metabolite of norepinephrine dihydroxyphenylglycol 
and of tritium-labeled norepinephrine. The latter eport was in 
Table 3. Binding Characteristics of Hydrogen-3 Mazindol to Human 
Left Ventricular Membrane Preparations 
Bmux 
(fmol H-3 mazindol K D 
bound/mg protein) (nmol/liter) 
NF (n = 5) 1,102 _+ 37 27.0 (22.1-33.1) 
NYHA lI-III (n = 5) 724 _+ 77* 36.4 (22.4-59.2) 
NYHA IV (n = 9) 809 ± 52* 28.4 (23.7-34.1) 
*p < 0.05 versus nonfailing myocardium (NF). Data presented are mean 
value +_ SEM or value (range). Bm~ , = maximal number of binding sites; KD - 
dissociation constant; NYHA = New York Heart Association functional class 
(see Table I). 
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favor of an increased neuronal firing rate of sympathetic nerves 
in the presence of unchanged neuronal uptake. 
The discrepancies among available studies are apparently 
influenced by the different techniques used and the problem of 
differentiating between sympathetic a tivity and catecholamine 
uptake-1 in vivo. 
Cardiac uptake-1 and contractility. To overcome the prob- 
lems inherent in in vivo studies, we investigated the effects of 
norepinephrine compared with isoproterenol, which is not a 
substrate of uptake-l, uptake into presynaptic stores (15,16) in 
isolated human myocardium in vitro. The efficiency of both 
beta-adrenoceptor agonists in increasing force of contraction 
was reduced in relation to severity of heart failure. These 
findings were reported earlier by several groups (1-3,27) and 
might be related to postsynaptic alterations in beta-adrenergic 
signal transduction involving beta-adrenoceptor down- 
regulation or uncoupling (1-3,28) and increased levels of 
myocardial Gi-alpha (4-6). However, the opposite results 
were obtained with the two beta-adrenergic agonists when 
their potency was compared. As expected, and as previously 
reported (1), the potency of isoproterenol was observed to be 
reduced in failing myocardium. This could be the result of 
beta-adrenoceptor uncoupling and down-regulation (1,2,27,28). 
However, the potency of norepinephrine to increase force of 
contraction was increased in failing human myocardium. 
This finding is compatible with the concept that exog- 
enously applied norepinephrine is not inactivated because of a 
reduced capacity for norepinephrine uptake. If this were the 
case, one would expect hat the concentration-response curve 
of norepinephrine would be affected ifferently by norepineph- 
rine uptake-1 inhibitors, such as desipramine or cocaine. 
Indeed, cocaine and desipramine shifted the concentration- 
response curves of norepinephrine to the left in nonfailing 
myocardium but did not affect the effect of norepinephrine in 
failing human myocardium. Thus, another discrepancy exists 
between the in vivo data reported by Meredith et al. (11) and 
the in vitro data on isolated myocardium reported in the 
present study, some of which could be due to the fact that 
Meredith et al. (11) studied in vivo norepinephrine uptake in 
patients with moderate heart failure. Thus, norepinephrine 
uptake in the whole heart, including the vasculature and the 
arteries, is determined by using the techniques of Meredith et 
al. (11). The experiments performed in the present study 
exclusively address alterations in norepinepbrine uptake in left 
ventricular myocardium. Conclusions drawn from these data 
cannot be uncritically extrapolated toother parts of the heart, 
such as the arteries or vasculature. Therefore, the different 
results indirectly indicate evidence of differences in norepi- 
nephrine uptake or even sympathetic nnervation of different 
parts or components of the failing human heart. Finally, 
Meredith et al. (11) studied patients with hypertension or 
ischemic heart disease, or both, at the stage of moderate heart 
failure. In the present study, we evaluated myocardium from 
patients with terminal heart failure due to ischemic dilated 
cardiomyopathy as well as myocardial tissue from patients with 
mitral valve replacement. Therefore, the underlying cardiac 
disease could also have affected these differences. 
Norepinephrine uptake carrier sites in isolated myocardial 
membranes. To substantiate functional findings with a bio- 
chemical technique, we labeled norepinephrine uptake-1 car- 
rier sites with the radioligand H-3 mazindol. This compound 
has been reported to label catecholamine uptake carrier sites 
in the brain (18). In the present study, we observed a significant 
reduction by -40% in H-3 mazindol binding sites in left 
ventricular particulate fractions from failing hearts compared 
with fractions from nonfailing hearts. In right heart failure in 
dogs caused by tricuspid valve avulsion, Liang et al. (29) 
reported a significant reduction by -50% of H-3 mazindol 
binding sites in the right but not left ventricle. The reduction of 
binding sites closely was correlated with the depressed norepi- 
nephrine uptake activity in the same hearts. These investiga- 
tors concluded that local mechanisms could be related to the 
impairment of norepinephrine uptake confined to the right 
ventricle in their model. Norepinephrine uptake inhibitors 
failed to influence the concentration-response curve for nor- 
epinephrine, although the number of H-3 mazindol binding 
sites was reduced by 30%. Thus, a large portion of uptake-1 
carriers in the present study of human heart might not 
participate in active norepinephrine inactivation. 
Study limitations, A potential limitation of the radioligand 
binding experiments i the use of a high concentration of 
desipramine (100/zmol/liter) todetermine nonspecific binding 
in experiments characterizing norepinephrine uptake carrier 
sites in human ventricular tissue. Thus it is possible that 
desipramine displaces H-3 mazindol binding from nonspecific 
binding sites. However, we could not reproduce the data of 
Liang et al. (29), who reported numbers of H-3 mazindol 
binding sites similar to those herein by using 0.3 ~mol/liter of 
desipramine. Thus, H-3 mazindol binding to human myocar- 
dial membranes i more similar to binding sites in striatal 
membranes, where -30 to 100 /~mol/liter of desipramine is
necessary to displace H-3 mazindol binding (18). Such difficul- 
ties in quantifying norepinephrine uptake carrier sites by 
binding experiments emphasize the necessity of applying func- 
tional as well as biochemical methods to investigate reduced 
norepinephrine uptake-1 in failing myocardium. 
Evidence for a reduction in norepinephrine uptake effects 
has been observed in the transplanted human heart. After 
transplantation, degeneration f the postganglionic ventricular 
nerve terminal has been observed in histologic (30) and 
immunohistologic (31) investigations. Consistently, as in the 
failing human heart (21,22), norepinephrine depletion occurs 
in the transplanted heart (26,32). Failing myocardium is also 
similar to transplanted heart myocardium with regard to 
uptake mechanisms. In heart ransplant recipients the effect of 
epinephrine on myocardial force of contraction was observed 
to increase in vivo, whereas the effect of isoproterenol was 
unchanged (33). Desipramine treatment in healthy volunteers 
enhanced the effect of epinephrine but was ineffective in heart 
transplant recipients (33). To our knowledge these are the first 
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Figure 6. Scheme of functional defects in the failing human myocar- 
dium. Down-regulation of cardiac beta-adrenoceptors (/3-AR) and an 
increase in inhibitory guanine binding proteins (Gcalpha) lead to a 
reduced formation of the intracellular second messenger cyclic aden- 
osine monophosphate (cAMP). In addition to these postsynaptic 
changes, there could be a presynaptic defect in the sympathetic nerve 
system consisting of a reduced density of norepinephrine uptake 
carrier sites. The consequence could be an increase in the concentra- 
tion of norepinephrine in the synaptic cleft. AC = adenylyl cyclase; 
ATP = adenosine triphosphate; M-Ch = m-cholinoceptors; o/i(Ors) : 
Gi (G~)-protein subunit alpha; /3 (7) = G-protein subunit beta 
(gamma). 
findings to demonstrate he similarity of the failing and the 
transplanted human heart. 
Clinical implications. In patients with heart failure as well 
as in heart transplant recipients, there will be a higher ratio of 
inotropic to vasconstrictor effects (i.e., a higher ratio of beta- 
adrenergic to alpha-adrenergic stimulation). These findings 
indicate some important consequences in the initiation of 
postsynaptic adenylyl cyclase desensitization of the failing 
heart. A defective norepinephrine uptake could contribute to 
high concentrations of norepinephrine in the synaptic left. In 
addition, elevated plasma norepinephrine concentrations con- 
tribute to beta-adrenoceptor down-regulation even in situa- 
tions in which the release of norepinephrine from the sympa- 
thetic cardiac neurons is low because cardiac norepinephrine is 
not inactivated by uptake-1. The latter hypothesis has been 
substantiated in the dog model. Norepinephrine infusion failed 
to reduce beta-adrenoceptor numbers in dogs with an intact 
myocardial norepinephrine uptake mechanism (34), but beta- 
adrenoceptor down-regulation was observed in dogs after 
cardiac denervation (34), a condition that is known to impair 
myocardial norepinephrine uptake (35). Thus, defective nor- 
epinephrine uptake into presynaptic stores is likely to contrib- 
ute to adenylyl cyclase desensitization, which is regarded as an 
important mechanism of myocardial dysfunction i  heart fail- 
ure (Fig. 6). 
Conclusions. Functional and biochemical evidence indi- 
cate that norepinephrine uptake is impaired in failing human 
hearts. This defect is likely to alter the profile of the hemody- 
namic response to norepinephrine in vivo and might play a 
pathophysiologically important role in generating postsynaptic 
alterations, such as beta-adrenoceptor down-regulation and 
increased Gi-alpha levels, leading to adenylyl cyclase desensi- 
tization. 
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